A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-03-31
AEs
4
Serious
1
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-02 (study day 84); relationship: Y
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 204); relationship: N
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 213); relationship: not assessed
severe
serious
assessed
Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 227); relationship: not assessed; serious criteria: life-threatening
Data queries
No data queries.